Market Ripples from Merck’s Acquisition of Idenix
Insights - The announcement that Merck (MRK) plans to acquire Idenix Pharmaceuticals (IDIX) for $3.85 billion, or $24.50 per share, is having a ripple effect on the … Continue Reading
Read nowAuthor Archives: Editorial Staff
Two Items of Note This Friday Evening
Recap - First, we’re hosting a networking event for healthcare investors, traders, and analysts on June 17th – details and RSVP here. It’s all about dialog, an investor’s best friend when you’ve … Continue Reading
Read now
Regulatory Path for Prosensa’s DMD Drug Just Got Clarity
Insights - Prosensa (RNA) will seek FDA and European approval for drisapersen, its drug candidate for Duchenne Muscular Dystrophy, following correspondence with the US regulatory body and what appears … Continue Reading
Read nowWeekly Recap: Two Picks In Two Weeks Climbed Twenty Percent Each
Recap - These trades aren’t over yet, and you can catch up on the fundamental theses at PropThink.com. Below, our weekly recap. Shares of Biodelivery Sciences (BDSI) came close to … Continue Reading
Read now
Ventrus-Assembly Merger Brings Novel HBV Technology Public
Insights - Ventrus and Assembly Pharma plan to merge to develop their novel HBV te.chnology
Read nowFinally. An Encouraging Week in Biotech
Research - The sector-tracking iShares NASDAQ biotechnology ETF (IBB) took out some major levels of resistance in the Thursday trading session, catching the attention of traders in the … Continue Reading
Read now
FDA Kicks the Can Down the Road for Keryx’s Lead Drug
Insights - The FDA extended the approval decision date for Zerenex (ferric citrate) by 3 months, to September 7, following revisions to Keryx’s new drug application.
Read now